Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 10/20 | 0.54 |
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787657 | 0.79 | MAP3K5 (0.65) | JAK1JAK2MAP3K5 | |
| Cyclohexane SCHEMBL16986948 | 0.78 | JAK1 (0.53) | JAK1JAK2JAK3TYK2EGLN2 | |
| SCHEMBL13031190 | 0.76 | JAK1 (0.73) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL2790092 | 0.75 | JAK2 (0.53) | JAK1JAK2TYK2MAP3K5 | |
| SCHEMBL13031192 | 0.74 | JAK1 (0.70) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL2787822 | 0.73 | MAP3K5 (0.62) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL13031290 | 0.72 | JAK1 (0.81) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL13031292 | 0.72 | JAK1 (0.80) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL13031288 | 0.70 | JAK1 (1.00) | JAK1JAK2JAK3IKBKBRIPK2 | |
| SCHEMBL13031291 | 0.68 | JAK1 (0.78) | JAK1JAK2JAK3IKBKBRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | claimed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | claimed |
| EP-2217578-B9 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-09-10 | — | — | EP | claimed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | claimed |
| EP-2217578-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2013-12-04 | — | — | EP | claimed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | claimed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | claimed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | claimed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | claimed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885JAK2 16/4885JAK3 40/4885 |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | ITK, PIK3C3, TXK | JAK1 13/4885JAK2 41/4885JAK3 35/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885JAK2 16/4885JAK3 40/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885JAK2 16/4885JAK3 40/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885JAK2 16/4885JAK3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.